`
 
Timothy P. Clackson, PhD
Home
About Us
Structure
Current Events
Past Events
Policy & Reports
Awards
Membership
Media Coverage
Internship/Volunteers
Legal
Contact Us
 
 
Timothy P. Clackson, PhD
President of R&D and Chief Scientific Officer
Ariad

Tim Clackson is President of Research and Development and Chief Scientific Officer at ARIAD Pharmaceuticals Inc., now a wholly owned subsidiary of Takeda (since February 2017). During his 22 year career at ARIAD, Dr. Clackson held a series of increasingly senior positions, including Chief Scientific Officer from 2003 and President of R&D from 2010. Dr. Clackson had overall operational and strategic responsibility for R&D at ARIAD, including drug discovery, preclinical and translational research, clinical development, medical affairs, and technical operations. From project conception to approval, he led the multi-disciplinary R&D team that discovered and developed ICLUSIG (ponatinib), a pan-BCR-ABL inhibitor now approved in approximately 50 countries for the treatment of resistant CML and Ph+ALL; and ALUNBRIG (brigatinib), a next-generation ALK inhibitor recently approved in the US. His team also developed AP32788 (an EGFR/HER2 inhibitor in phase 1/2 development), ridaforolimus (an mTOR inhibitor under review for approval on drug eluting stents, licensed to Medinol) and rimiducid (a small molecule regulator for cancer cell therapy in phase 2 testing licensed to Bellicum Pharmaceuticals). Dr Clackson also led the earlier development of a widely-used platform technology for small molecule “dimerizer” control of gene and cell activity.

From 1991 to 1994, Dr. Clackson was a postdoctoral fellow at Genentech Inc., where his studies on growth hormone receptor defined the now-established “hot spot” paradigm for how proteins interact. He received his PhD in Biology from Cambridge University in 1991, for research conducted under Dr Greg Winter, FRS at the MRC Laboratory of Molecular Biology into antibody engineering and the development of antibody phage display technology, subsequently commercialized by Cambridge Antibody Technology. Dr. Clackson has published approximately 100 scientific papers, book chapters and reviews, and is a co-inventor on 15 issued U.S. patents. He received his PhD in Biology from Cambridge University in 1991, and his B.A. degree in Biochemistry from Oxford University in 1987.

© 2007 - USA India Chamber of Commerce Home | About us | Agenda | Council | Policy | Events | Photo Gallery | Awards | Membership | Membership Form | Internship/Volunteers | Legal | Contact us